Company profile
Akari Therapeutics Plc
NASDAQ:AKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NOMACOPAN | phase3 | — | 4 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03427060 | phase2 | completed | 2018-05-14 | 2018-11-15 | AKARI Therapeutics | Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms |
| NCT02591862 | phase2 | completed | 2016-02-01 | 2018-03-20 | AKARI Therapeutics | Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) |
| NCT04784455 | phase3 | terminated | 2021-02-01 | 2024-05-15 | AKARI Therapeutics | Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy |
| NCT05061771 | phase3 | withdrawn | 2022-05-06 | 2022-08-01 | AKARI Therapeutics | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) |
| NCT04037891 | phase1_2 | terminated | 2019-03-04 | 2020-04-30 | AKARI Therapeutics | Topical rVA576 for Treatment of Atopic Keratoconjunctivitis |
FDA applications (0)
No records yet.